Cytisinicline, a plant-based alkaloid used as a smoking cessation ingredient available OTC in some Central and Eastern Europe countries, has shown strong results in two phase 3 studies by a US firm preparing to ask the Food and Drug Administration for approval as a new drug.
Although Achieve Life Sciences Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?